Triptolide Inhibits Osteoclast Differentiation and Bone Resorption In Vitro via Enhancing the Production of IL-10 and TGF-β1 by Regulatory T Cells

Figure 2

The effect of different concentrations of triptolide on BMMs or Tregs. (a) Mouse BMMs were treated with triptolide (2.5, 5, 10, 20, or 40 nM) in the absence of M-CSF and RANKL. TRAP activity was measured at a wavelength of 405 nm as described above. (b) Mouse BMMs were treated with triptolide (2.5, 5, 10, 20, or 40 nM) in the absence of M-CSF and RANKL. Cell viability was measured at a wavelength of 450 nm using the CCK-8 assay. (c) Activated Tregs were treated with triptolide (2.5, 5, 10, 20, or 40 nM), and cell viability was measured at a wavelength of 450 nm using the CCK-8 assay. and compared with the control group (TP 0 nM group).

(a)

(b)

(c)